Importance of SALL4 in the development and prognosis of hepatocellular carcinoma

Table 2 Relationship between the expression of SALL4 and clinical characteristics in hepatocellular carcinoma patients

Parameters	SALL4 (-/+)	P value1	P value2
Clinical stages
Ia	11/7
Ib	17/8
IIa	21/13
IIb	11/18
IIIa	8/12	0.034	0.006
Histological differentiation
Well	9/4
Moderate	30/23
Poor	29/31	0.344	0.069
BCLC stages
A	53/29
B	3/2
C	12/27	0.001	0.000
Sex
Male	57/50
Female	11/8	0.931	0.932
Age (yr)
< 50	24/21
≥ 50	44/37	0.918	0.918
Tumor diameter (cm)
< 3	6/6
3-5	22/12
5-10	24/22
≥ 10	16/18	0.176	0.042
Platelet
(× 109/L)
< 100	9/11
100-200	47/32
200-300	9/12
≥ 300	3/3	0.231	0.863
Vascular invasion
With	11/21
Without	57/37	0.004	0.004
HBsAg
Positive	58/51
Negative	10/7	0.487	0.490
HBeAb
Positive	28/19
Negative	40/39	0.359	0.361
Child-Pugh
Child A	67/57
Child B	1/1	0.822	0.823
AFP (μg/L)
< 7	9/7
7-100	26/8
100-400	10/12
400-800	5/4
800-1210	0/2
≥ 1210	18/25	0.013	0.003

¹P value was obtained by non-parametric test;

²P value was obtained by Spearman correlation. AFP: α-fetoprotein; SALL4: Sal-like protein 4.